Osteopontin as a therapeutic target for cancer

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 8, 2014, Pages 883-895

  Bandopadhyay, Monalisa ^a   Bulbule, Anuradha ^a   Butti, Ramesh ^a   Chakraborty, Goutam ^b   Ghorpade, Priyanka ^a   Ghosh, Pompom ^a   Gorain, Mahadeo ^a   Kale, Smita ^a   Kumar, Dhiraj ^a   Kumar, Santosh ^a   Totakura, Kumar Vs ^a   Roy, Gaurab ^a   Sharma, Priyanka ^a   Shetti, Dattatrya ^a   Soundararajan, Gowrishankar ^a   Thorat, Dhanashri ^a   Tomar, Deepti ^a   Nalukurthi, Radha ^a   Raja, Remya ^a   Mishra, Rosalin ^a   Yadav, Amit S ^a   Kundu, Gopal C ^a   more..

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Angiogenesis; Biomarker; Hypoxia; Osteopontin; RNAi technology; Stroma; Targeted therapy

Indexed keywords

ANTIBODY; APTAMER; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OSTEOPONTIN; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; BREAST TUMOR; CANCER THERAPY; CARCINOGENIC ACTIVITY; CELL HYPOXIA; HUMAN; INTRACELLULAR SIGNALING; MACROPHAGE; META ANALYSIS (TOPIC); METASTASIS; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; STROMA CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; CELL PROLIFERATION; DISEASE COURSE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOPONTIN; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84904410186     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.925447     Document Type: Review

References (100)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74.
2. Wels J, Kaplan RN, Rafii S, et al. Migratory neighbors and distant invaders: Tumor-associated niche cells. Genes Dev 2008;22:559-74 (Pubitemid 351342429)
3. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: Role in cell signalling and cancer progression. Trends Cell Biol 2006;16:79-87. (Pubitemid 43247403)
4. Chakraborty G, Jain S, Behera R, et al. The multifaceted roles of osteopontin in cell signalling, tumor progression and angiogenesis. Curr Mol Med 2006;6:819-30. (Pubitemid 44883934)
5. Wang KX, Denhardt DT. Osteopontin: Role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008;19:333-45
6. Denhardt DT, Noda M, O'Regan AW, et al. Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055-61 (Pubitemid 32422899)
7. Denhardt DT, Guo X. Osteopontin: A protein with diverse functions. FASEB J 1993;7:1475-82. (Pubitemid 24003267)
8. Solinas G, Schiarea S, Liguori M, et al. Tumor-conditioned macrophages secrete migration-stimulating factor: A new marker for M2-polarization influencing tumor cell motility. J Immunol 2010;185:642-52
9. Fedarko NS, Jain A, Karadag A, et al. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001;7:4060-6 (Pubitemid 34044628)
10. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010;103:861-9
11. Thorat D, Sahu A, Behera R, et al. Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers. Oncol Lett 2013;6:1559-64
12. Raja R, Kale S, Thorat D, et al. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1a-mediated VEGF-dependent angiogenesis. Oncogene 2014;33(16):2053-64.
13. Pazolli E, Luo X, Brehm S, et al. Senescent stromal-derived osteopontin promotes preneoplastic cell growth. Cancer Res 2009;69:1230-9
14. Kumar S, Sharma P, Kumar D, et al. Functional characterization of stromal osteopontin in melanoma progression and metastasis. PLoS One 2013;8:e69116
15. Kale S, Raja R, Thorat D, et al. Osteopontin signalling upregulates cyclooxygenase-2 expression in tumorassociated macrophages leading to enhanced angiogenesis and melanoma growth via alpha9beta1 integrin. Oncogene 2014;33(18):2295-306.
16. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through NF-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 2001;276:44926-35
17. Philip S, Kundu GC. Osteopontin induces NF-kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signalling pathways and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 2003;278:14487-97 (Pubitemid 36800002)
18. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor inducing kinase plays crucial role in osteopontin-induced MAPK/IKK dependent nuclear factor kB-mediated promatrix metalloproteinase-9 activation. J Biol Chem 2004;279:38921-35 (Pubitemid 39296053)
19. Takahashi F, Takahashi K, Shimizu K, et al. Osteopontin is strongly expressed by alveolar macrophages in the lungs of acute respiratory distress syndrome. Lung 2004;182:173-85 (Pubitemid 38982215)
20. Banerjee A, Burghardt RC, Johnson GA, et al. The temporal expression of osteopontin (SPP-1) in the rodent model of alcoholic steatohepatitis: A potential biomarker. Toxicol Pathol 2006;34:373-84
21. Nagasaka A, Matsue H, Matsushima H, et al. Osteopontin is produced by mast cells and affects IgE-mediated degranulation and migration of mast cells. Eur J Immunol 2008;38:489-99
22. Santamaŕa MH, Corral RS. Osteopontin-dependent regulation of Th1 and Th17 cytokine responses in Trypanosoma cruzi-infected C57BL/6mice. Cytokine 2013;61:491-08
23. Li X, Qi Y, Ma X, et al. Chemokine (C-C motif) ligand 20, a potential biomarker for Graves' disease, is regulated by osteopontin. PLoS One 2013;8:e64277
24. Ohyama Y, Nemoto H, Rittling S, et al. Osteopontin-deficiency suppresses growth of B16 melanoma cells implanted in bone and osteoclastogenesis in co-cultures. J Bone Miner Res 2004;19:1706-11 (Pubitemid 41094334)
25. Prince CW, Oosawa T, Butler WT, et al. Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chem 1987;262:2900-7.
26. Young MF, Kerr JM, Termine JD, et al. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 1990;7:491-502 (Pubitemid 20244451)
27. Oldberg A, Franzén A, Heinega°rd D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cellbinding sequence. Proc Natl Acad Sci USA 1986;83:8819-23. (Pubitemid 17223492)
28. Beausoleil MS, Schulze EB, Goodale D, et al. Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis. BMC Cancer 2011;11:25
29. He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 2006;25:2192-202.
30. Mirza M, Shaughnessy E, Hurley JK, et al. Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008;122:889-97
31. Tilli TM, Mello KD, Ferreira LB, et al. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 2012;72:1688-99
32. Zheng W, Li R, Pan H, et al. Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum 2009;60:1957-65
33. Yokosaki Y, Matsuura N, Sasaki T, et al. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 1999;274:36328-34
34. Yokosaki Y, Tanaka K, Higashikawa F, et al. Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin. Matrix Biol 2005;24:418-27 (Pubitemid 41765020)
35. Cui R, Takahashi F, Ohashi R, et al. Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer 2007;57:302-10 (Pubitemid 47285419)
36. Stemberger C, Matusan-Ilijas K, Avirović M, et al. Osteopontin is associated with decreased apoptosis and av integrin expression in lung adenocarcinoma. Acta Histochem 2014;116:222-9
37. Wang XM, Li J, Yan MX, et al. Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer. PLoS One 2013;8:e55714
38. Zohar R, Suzuki N, Suzuki K, et al. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 2000;184:118-30 (Pubitemid 30349635)
39. Jijiwa M, Demir H, Gupta S, et al. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One 2011;6:e24217
40. Kumar V, Behera R, Lohite K, et al. p38 Kinase is crucial for osteopontininduced furin expression that supports cervical cancer progression. Cancer Res 2010;70:10381-91
41. Jain S, Chakraborty G, Bulbule A, et al. Osteopontin: An emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets 2007;11:81-90 (Pubitemid 46099754)
42. Robertson BW, Chellaiah MA. Osteopontin induces beta-catenin signalling through activation of Akt in prostate cancer cells. Exp Cell Res 2010;316:1-11
43. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin induces AP-1 mediated secretion of urokinase-type plasminogen activator through c-Src-dependent EGF receptor transactivation in breast cancer cells. J Biol Chem 2004;279:11051-64 (Pubitemid 38401597)
44. Zhang R, Pan X, Huang Z, et al. Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS One 2011;6:e23831
45. Matusan-Ilijas K, Damante G, Fabbro D, et al. Osteopontin expression correlates with nuclear factor-kB activation and apoptosis down regulation in clear cell renal cell carcinoma. Pathol Res Pract 2011;207:104-10
46. Mutrie JC, Chambers AF, Tuck AB. Osteopontin increases breast cancer cell sensitivity to specific signalling pathway inhibitors in preclinical models. Cancer Biol Ther 2011;12:680-90
47. Behera R, Kumar V, Lohite K, et al. Activation of JAK2/STAT3 signalling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis 2010;31:192-200
48. Chen RX, Xia YH, Xue TC, et al. Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA. Oncol Rep 2011;25:803-8
49. Kaomongkolgit R, Manokawinchoke J, Sanchavanakit N. Fibronectin supports TNF-alpha-induced osteopontin expression through beta1integrin and ERK in HN-22 cells. Arch Oral Biol 2010;55:101-7
50. Tilli TM, Franco VF, Robbs BK, et al. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res 2011;9:280-93
51. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes VEGF-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 2008;68:152-61. (Pubitemid 351380116)
52. Jain S, Chakraborty G, Kundu GC. The crucial role of cyclooxygenase-2 in osteopontin-induced PKCalpha/c-Src/IKKalpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Res 2006;66:6638-48 (Pubitemid 44085620)
53. Le QT, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. Cancer Metastasis Rev 2004;23:293-310 (Pubitemid 38881813)
54. Cowden Dahl KD, Robertson SE, Weaver VM, et al. Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression. Mol Biol Cell 2005;16:1901-12 (Pubitemid 40471958)
55. Zhu Y, Denhardt DT, Cao H, et al. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 2005;24:6555-63 (Pubitemid 41486638)
56. Storti P, Bolzoni M, Donofrio G, et al. Hypoxia-inducible factor (HIF)-1alpha suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia 2013;27:1697-706
57. Yang L, Zhao W, Zuo WS, et al. Silencing of osteopontin promotes the radiosensitivity of breast cancer cells by reducing the expression of hypoxia inducible factor 1 and vascular endothelial growth factor. Chin Med J (Engl) 2012;125:293-9
58. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423-37.
59. Pazolli E, Alspach E, Milczarek A, et al. Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression. Cancer Res 2012;72:2251-61
60. Liu J, Xu K, Chase M, et al. Tiam1-regulated osteopontin in senescent fibroblasts contributes to the migration and invasion of associated epithelial cells. J Cell Sci 2012;125:376-86
61. Luo X, Ruhland MK, Pazolli E, et al. Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway. Mol Cancer Res 2011;9:1018-29
62. Li NY, Weber CE, Mi Z, et al. Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype. J Am Coll Surg 2013;217:17-26.
63. Zou C, Song G, Luo Q, et al. Mesenchymal stem cells require integrin beta1 for directed migration induced by osteopontin in vitro. In Vitro Cell Dev Biol Anim 2011;47:241-50
64. Zou C, Luo Q, Qin J, et al. Osteopontin promotes mesenchymal stem cell migration and lessens cell stiffness via integrin beta1, FAK and ERK pathways. Cell Biochem Biophys 2013;65:455-62
65. Bhattacharya SD, Mi Z, Talbot LJ, et al. Human mesenchymal stem cell and epithelial hepatic carcinoma cell lines in admixture: Concurrent stimulation of cancer-associated fibroblasts and epithelial-to-mesenchymal transition markers. Surgery 2012;152:449-54
66. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11 (Pubitemid 28099681)
67. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8 (Pubitemid 32494397)
68. Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet 2011;12:329-40
69. Chakraborty G, Jain S, Patil TV, et al. Down-regulation of osteopontin attenuates breast tumor progression in vivo. J Cell Mol Med 2008;12:2305-18
70. Tajima K, Ohashi R, Sekido Y, et al. Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene 2010;29:1941-51
71. Yang L, Wei L, Zhao W, et al. Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells. Mol Med Rep 2012;5:373-6
72. Bhattacharya SD, Garrison J, Guo H, et al. Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines. Surgery 2010;148:291-7
73. Zhang Y, Forootan SS, Kamalian L, et al. Suppressing tumourigenicity of prostate cancer cells by inhibiting osteopontin expression. Int J Oncol 2011;38:1083-91
74. Sharma P, Kumar S, Kundu GC. Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Mol Cancer 2010;9:178
75. Zagani R, Hamzaoui N, Cacheux W, et al. Cyclooxygenase-2 inhibitors downregulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers. Gastroenterology 2009;137:1358-66
76. Matsuura M, Suzuki T, Saito T. Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy. Cancer Sci 2010;101:1828-33
77. Lv J, Shao Q, Wang H, et al. Effects and mechanisms of curcumin and basil polysaccharide on the invasion of SKOV3 cells and dendritic cells. Mol Med Rep 2013;8:1580-6
78. Kumar S, Patil HS, Sharma P, et al. Andrographolide inhibits osteopontin expression and breast tumor growth through down regulation of PI3 kinase/Akt signalling pathway. Curr Mol Med 2012;12:952-66
79. Mi Z, Guo H, Wai PY, et al. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis 2006;27:1134-45 (Pubitemid 43985428)
80. Ahmed M, Kundu GC. Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kB dependent AP-1-mediated ICAM-1 expression in breast cancer cells. Mol Cancer 2010;9:101
81. Dai J, Peng L, Fan K, et al. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene 2009;28:3412-22
82. Dai J, Li B, Shi J, et al. A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother 2010;59:355-66
83. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 2010;46:1271-7
84. Ahmed M, Behera R, Chakraborty G, et al. Osteopontin: A potentially important therapeutic target in cancer. Expert Opin Ther Targets 2011;15:1113-26
85. Rajasagi M, von Au A, Singh R, et al. Anti-CD44 induces apoptosis in T lymphoma via mitochondrial depolarization. J Cell Mol Med 2010;14:1453-67
86. Teramoto H, Castellone MD, Malek RL, et al. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene 2005;24:489-501 (Pubitemid 40188596)
87. Mi Z, Guo H, Russell MB, et al. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB-231 breast cancer cells. Mol Ther 2009;17:153-61
88. Hunter C, Bond J, Kuo PC, et al. The role of osteopontin and osteopontin aptamer (OPN-R3) in fibroblast activity. J Surg Res 2012;176:348-58
89. Talbot LJ, Mi Z, Bhattacharya SD, et al. Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells. Surgery 2011;150:224-30
90. Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998;58:5206-15 (Pubitemid 28521184)
91. Bourassa B, Monaghan S, Rittling SR. Impaired anti-tumor cytotoxicity of macrophages from osteopontin-deficient mice. Cell Immunol 2004;227:1-11 (Pubitemid 38393724)
92. Weber GF, Lett GS, Haubein NC. Categorical meta-analysis of osteopontin as a clinical cancer marker. Oncol Rep 2011;25:433-41.
93. Konieczna L, Skokowski J, Oledzka I, et al. The osteopontin tissue level as a breast cancer biomarker in females after mastectomy measured by the capillary gel electrophoresis technique. Comb Chem High Throughput Screen 2013;16:331-8
94. Cao DX, Li ZJ, Jiang XO, et al. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol 2012;18:3923-30
95. Zhao L, Wang Y, Qu N, et al. Significance of plasma osteopontin levels in patients with bladder urothelial carcinomas. Mol DiagnTher 2012;16:311-6
96. Yamaguchi Y, Shao Z, Sharif S, et al. Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage. J Biol Chem 2013;288:3097-111
97. Han SS, Lee SJ, Kim WJ, et al. Plasma osteopontin is a useful diagnostic biomarker for advanced non-small cell lung cancer. Tuberc Respir Dis (Seoul) 2013;75:104-10
98. Rud AK, Boye K, Oijordsbakken M, et al. Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer 2013;13:540
99. Thoms JW, Dal Pra A, Anborgh PH, et al. Plasma osteopontin as a biomarker of prostate cancer aggression: Relationship to risk category and treatment response. Br J Cancer 2012;107:840-6
100. Mason CK, McFarlane S, Johnston PG, et al. Agelastatin A: A novel inhibitor of osteopontin-mediated adhesion, invasion and colony formation. Mol Cancer Ther 2008;7:548-58 (Pubitemid 351482138)